Clinical Trial Update: LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating LY4268989 (MORF-057) in combination with mirikizumab for adults with moderately to severely active ulcerative colitis is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• LY4268989 (MORF-057) (LY4268989)
• Mirikizumab (mirikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Ulcerative Colitis | Phase 2 | Status: RECRUITING